benserazide has been researched along with Parkinson Disease, Secondary in 35 studies
Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The bioavailability of levodopa-benserazide in a standard capsule and a new dispersible tablet was compared in Parkinsonian patients, with (n = 8) and without (n = 8) swallowing difficulties." | 6.66 | Bioavailability and acceptability of a dispersible formulation of levodopa-benserazide in parkinsonian patients with and without dysphagia. ( Bayer, AJ; Day, JJ; Finucane, P; Pathy, MS, 1988) |
| "Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced parkinsonian symptoms, predominantly bradykinesia and tremor, in marmosets." | 3.67 | Failure of SKF 38393-A to relieve parkinsonian symptoms induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset. ( Close, SP; Marriott, AS; Pay, S, 1985) |
| "Temazepam was consistently less potent than chlormethiazole on tests of drowsiness and psychomotor performance." | 2.67 | A single-dose study of the pharmacodynamic effects of chlormethiazole, temazepam and placebo in elderly parkinsonian patients. ( Ashwood, TJ; Bateman, DN; Tulloch, JA; Woodhouse, KW, 1991) |
| "The bioavailability of levodopa-benserazide in a standard capsule and a new dispersible tablet was compared in Parkinsonian patients, with (n = 8) and without (n = 8) swallowing difficulties." | 2.66 | Bioavailability and acceptability of a dispersible formulation of levodopa-benserazide in parkinsonian patients with and without dysphagia. ( Bayer, AJ; Day, JJ; Finucane, P; Pathy, MS, 1988) |
| "In 3 patients with longstanding Parkinson's disease treated with Madopar or Nacom, who were not included in the study, the doses of the above drugs could be maintained or reduced by addition of deprenyl." | 2.66 | Levodopa and monoamine oxidase inhibitor combination therapy. A controlled clinical trial. ( Grundmann, M; Schimrigk, K, 1987) |
| "Dyskinesias, confusional state and "on-off" phenomenon increased with time, whereas gastric trouble diminished." | 2.65 | [Efficacy and side-effects of long term L-dopa therapy in Parkinsonian syndromes (evaluated by CT scan as well) (author's transl)]. ( Del Pesce, M; Di Bella, P; Forastieri, L; Paggi, A; Quattrini, A, 1979) |
| "The mice developed catalepsy after 3 weeks on the LCa/Mg diet." | 1.39 | Combined low calcium and lack magnesium is a risk factor for motor deficit in mice. ( Nakagawasai, O; Nemoto, W; Sato, S; Tadano, T; Tan-no, K; Taniguchi, R; Yamadera, F; Yaoita, F, 2013) |
| " Long-term use of madopa developed a peak-dose dyskinesia of the face and the limbs contralateral to the MPTP-treated side." | 1.28 | [Dopa-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated hemiparkinsonian monkeys]. ( Chen, S, 1992) |
| "We have examined the effect of chronic administration of a probable endogenous dopaminergic neurotoxin, tetrahydroisoquinoline (TIQ, 20 mg/kg per day, s." | 1.28 | Parkinsonism in monkeys produced by chronic administration of an endogenous substance of the brain, tetrahydroisoquinoline: the behavioral and biochemical changes. ( Nagatsu, T; Niwa, T; Yoshida, M, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (31.43) | 18.7374 |
| 1990's | 11 (31.43) | 18.2507 |
| 2000's | 7 (20.00) | 29.6817 |
| 2010's | 5 (14.29) | 24.3611 |
| 2020's | 1 (2.86) | 2.80 |
| Authors | Studies |
|---|---|
| Che, NN | 1 |
| Chen, SY | 1 |
| Li, X | 1 |
| Ma, JJ | 1 |
| Yang, HQ | 1 |
| Loiodice, S | 1 |
| Wing Young, H | 1 |
| Rion, B | 1 |
| Méot, B | 1 |
| Montagne, P | 1 |
| Denibaud, AS | 1 |
| Viel, R | 1 |
| Drieu La Rochelle, C | 1 |
| Bersano, A | 1 |
| Aghemo, A | 1 |
| Rumi, MG | 1 |
| Ballabio, E | 1 |
| Candelise, L | 1 |
| Colombo, M | 1 |
| Yuan, CX | 1 |
| Ye, Q | 1 |
| Wang, J | 1 |
| Zhang, Y | 1 |
| Yuan, CG | 1 |
| Buck, K | 1 |
| Ferger, B | 1 |
| Dupre, KB | 1 |
| Ostock, CY | 1 |
| Eskow Jaunarajs, KL | 1 |
| Button, T | 1 |
| Savage, LM | 1 |
| Wolf, W | 1 |
| Bishop, C | 1 |
| Yin, LL | 1 |
| Geng, XC | 1 |
| Zhu, XZ | 1 |
| Ohlin, KE | 1 |
| Sebastianutto, I | 1 |
| Adkins, CE | 1 |
| Lundblad, C | 1 |
| Lockman, PR | 1 |
| Cenci, MA | 1 |
| Taniguchi, R | 1 |
| Nakagawasai, O | 1 |
| Tan-no, K | 1 |
| Yamadera, F | 1 |
| Nemoto, W | 1 |
| Sato, S | 1 |
| Yaoita, F | 1 |
| Tadano, T | 1 |
| Klintenberg, R | 1 |
| Svenningsson, P | 1 |
| Gunne, L | 1 |
| Andrén, PE | 1 |
| Wang, W | 1 |
| Zhao, DZ | 1 |
| Sun, XF | 1 |
| Gu, SD | 1 |
| Kamenetskiĭ, VK | 1 |
| Sarre, S | 1 |
| De Klippel, N | 1 |
| Herregodts, P | 1 |
| Ebinger, G | 1 |
| Michotte, Y | 1 |
| Olivé, JM | 1 |
| Masana, L | 1 |
| González, J | 1 |
| Imai, H | 1 |
| Nakamura, T | 1 |
| Kondo, T | 1 |
| Narabayashi, H | 1 |
| Papa, SM | 1 |
| Boldry, RC | 1 |
| Engber, TM | 1 |
| Kask, AM | 1 |
| Chase, TN | 1 |
| Kanda, T | 1 |
| Jackson, MJ | 1 |
| Smith, LA | 1 |
| Pearce, RK | 1 |
| Nakamura, J | 1 |
| Kase, H | 1 |
| Kuwana, Y | 1 |
| Jenner, P | 1 |
| Prevett, MC | 1 |
| Rossor, MN | 1 |
| Datla, KP | 1 |
| Blunt, SB | 1 |
| Dexter, DT | 1 |
| Barbosa, ER | 1 |
| Leiros da Costa, MD | 1 |
| Bacheschi, LA | 1 |
| Scaff, M | 1 |
| Leite, CC | 1 |
| Quattrini, A | 1 |
| Paggi, A | 1 |
| Forastieri, L | 1 |
| Del Pesce, M | 1 |
| Di Bella, P | 1 |
| Carolei, A | 1 |
| Casacchi, M | 1 |
| Fazio, C | 1 |
| Chen, S | 1 |
| Tulloch, JA | 1 |
| Ashwood, TJ | 1 |
| Bateman, DN | 1 |
| Woodhouse, KW | 1 |
| Morelli, M | 1 |
| Di Chiara, G | 1 |
| Yoshida, M | 1 |
| Niwa, T | 1 |
| Nagatsu, T | 1 |
| Pletscher, A | 1 |
| De Michele, G | 1 |
| Mengano, A | 1 |
| Filla, A | 1 |
| Trombetta, L | 1 |
| Campanella, G | 1 |
| Caraceni, T | 1 |
| Nordera, N | 1 |
| Lamperti, E | 1 |
| Lorizio, A | 1 |
| Hardie, RJ | 1 |
| Lees, AJ | 1 |
| Bayer, AJ | 1 |
| Day, JJ | 1 |
| Finucane, P | 1 |
| Pathy, MS | 1 |
| Grundmann, M | 1 |
| Schimrigk, K | 1 |
| Lieberman, AN | 1 |
| Close, SP | 1 |
| Marriott, AS | 1 |
| Pay, S | 1 |
| Castaigne, P | 1 |
| Rondot, P | 1 |
| Taberlet, A | 1 |
| Baumann, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia and Healthy Age Matched Controls; [11C]Yohimbine and [11C]MeNER PET[NCT02578849] | 45 participants (Anticipated) | Observational | 2012-01-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for benserazide and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Levodopa treatment of Parkinson's syndrome: past and future.
Topics: Benserazide; Brain; Carboxy-Lyases; Drug Therapy, Combination; Forecasting; Humans; Levodopa; Parkin | 1990 |
6 trials available for benserazide and Parkinson Disease, Secondary
| Article | Year |
|---|---|
[Efficacy and side-effects of long term L-dopa therapy in Parkinsonian syndromes (evaluated by CT scan as well) (author's transl)].
Topics: Adult; Benserazide; Brain; Carbidopa; Clinical Trials as Topic; Confusion; Electrocardiography; Elec | 1979 |
A single-dose study of the pharmacodynamic effects of chlormethiazole, temazepam and placebo in elderly parkinsonian patients.
Topics: Aged; Benserazide; Carbidopa; Chlormethiazole; Double-Blind Method; Drug Therapy, Combination; Femal | 1991 |
Levodopa treatment of Parkinson's syndrome: past and future.
Topics: Benserazide; Brain; Carboxy-Lyases; Drug Therapy, Combination; Forecasting; Humans; Levodopa; Parkin | 1990 |
A double-blind, cross-over trial with madopar HBS in patients with Parkinson's disease.
Topics: Adult; Aged; Benserazide; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Female; | 1989 |
Bioavailability and acceptability of a dispersible formulation of levodopa-benserazide in parkinsonian patients with and without dysphagia.
Topics: Aged; Aged, 80 and over; Benserazide; Biological Availability; Capsules; Consumer Behavior; Deglutit | 1988 |
Levodopa and monoamine oxidase inhibitor combination therapy. A controlled clinical trial.
Topics: Aged; Benserazide; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; | 1987 |
29 other studies available for benserazide and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Autoimmune-mediated secondary-parkinsonism presented with micrographia and cognitive impairment.
Topics: Adult; Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Antiparkinson Agents; Autoantibodies; Benser | 2021 |
Implication of nigral dopaminergic lesion and repeated L-dopa exposure in neuropsychiatric symptoms of Parkinson's disease.
Topics: Amphetamine; Animals; Antiparkinson Agents; Anxiety; Benserazide; Disease Models, Animal; Dopamine; | 2019 |
Recovery after L-DOPA treatment in peginterferon and ribavirin induced parkinsonism.
Topics: Antiparkinson Agents; Antiviral Agents; Benserazide; Drug Therapy, Combination; Humans; Interferon a | 2008 |
[Effects of traditional Chinese herbal medicine on the neurobehavioral manifestations and the activity of dopamine D2 receptor in corpora striatum of rats with levodopa-induced dyskinesias].
Topics: Animals; Benserazide; Corpus Striatum; Drugs, Chinese Herbal; Dyskinesias; Levodopa; Male; Oxidopami | 2008 |
Comparison of intrastriatal administration of noradrenaline and l-DOPA on dyskinetic movements: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine-lesioned rats.
Topics: Analysis of Variance; Animals; Benserazide; Corpus Striatum; Disease Models, Animal; Dopamine Agents | 2009 |
Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Benserazide; Benzazepines; Ch | 2011 |
The involvement of RGS9 in l-3,4-dihydroxyphenylalanine-induced dyskinesias in unilateral 6-OHDA lesion rat model.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Benserazide; Disease Models, Animal; D | 2011 |
Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease.
Topics: Algorithms; Animals; Antiparkinson Agents; Autoradiography; Basal Ganglia; Behavior, Animal; Bensera | 2012 |
Combined low calcium and lack magnesium is a risk factor for motor deficit in mice.
Topics: Amantadine; Animals; Antiparkinson Agents; Benserazide; Bromocriptine; Calcium; Catalepsy; Dopamine | 2013 |
Naloxone reduces levodopa-induced dyskinesias and apomorphine-induced rotations in primate models of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benserazide; Callithrix; Dopamine; Dopamine A | 2002 |
[The effect of shourong compound formula on levels of dopamine and its metabolites in brain of Parkinson's disease mice induced by reserpine].
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; Brain; Dopamine; Drug Combinations; Drug Syner | 2002 |
[Treatment of patients with vascular parkinsonism with the preparations nakom and madopar].
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Carbidopa; Drug Combinations; Humans; Hydrazines; Le | 1984 |
Biotransformation of locally applied L-dopa in the corpus striatum of the hemi-parkinsonian rat studied with microdialysis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; Biotransformation; Corpus Striatum; Denervatio | 1994 |
Meperidine and reversible parkinsonism.
Topics: Adult; Benserazide; Drug Therapy, Combination; Humans; Levodopa; Male; Meperidine; Neurologic Examin | 1994 |
Dopa-unresponsive pure akinesia or freezing. A condition within a wide spectrum of PSP?
Topics: Benserazide; Carbidopa; Diagnosis, Differential; Drug Therapy, Combination; Humans; Levodopa; Motor | 1993 |
Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade.
Topics: Animals; Antiparkinson Agents; Apomorphine; Benserazide; Dizocilpine Maleate; Excitatory Amino Acid | 1995 |
Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; B | 1998 |
Central pontine and extrapontine myelinolysis presenting with parkinsonism in a patient with cystic fibrosis.
Topics: Acute Disease; Adult; Antiparkinson Agents; Benserazide; Cystic Fibrosis; Drug Combinations; Humans; | 1999 |
Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Chlorides; Chro | 2001 |
Parkinsonism after glycine-derivate exposure.
Topics: Antiparkinson Agents; Benserazide; Drug Therapy, Combination; Globus Pallidus; Glycine; Glyphosate; | 2001 |
[Variations of the therapeutic action (on-off phenomenon) in patients with Parkin].
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Carbidopa; Humans; Levodopa; Parkinson Di | 1977 |
[Dopa-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated hemiparkinsonian monkeys].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamines; Animals; Apomorphine; Benserazide; Carbo | 1992 |
MK-801 potentiates dopaminergic D1 but reduces D2 responses in the 6-hydroxydopamine model of Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benserazide; Dizocilpine Maleat | 1990 |
Parkinsonism in monkeys produced by chronic administration of an endogenous substance of the brain, tetrahydroisoquinoline: the behavioral and biochemical changes.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Behavior, Animal; Benserazide; Biopterins; Br | 1990 |
Madopar HBS and the decompensated phase of Parkinson disease.
Topics: Adult; Aged; Benserazide; Delayed-Action Preparations; Drug Combinations; Female; Humans; Hydrazines | 1989 |
Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa.
Topics: Adult; Aged; Antipsychotic Agents; Benserazide; Drug Therapy, Combination; Female; Humans; Levodopa; | 1988 |
Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Benserazide; Carbidopa; Drug Ther | 1986 |
Failure of SKF 38393-A to relieve parkinsonian symptoms induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1985 |
[Variation in the pharmacologic affects of decarboxylase inhibitor in variable doses in man].
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Blood-Brain Barrier; Dose-Response Relati | 1974 |